Stereotaxis, Abbott Ink Pact To Combine Mapping & Robotic Tech: FDA Approves Abbott's Next-Gen Abalation Catheter

Benzinga ·  05/20 01:23

Stereotaxis Inc (NYSE:STXS) shares are gaining after the company announced a global collaboration with Abbott Laboratories (NYSE:ABT) to integrate Abbott's EnSite X EP System with Stereotaxis' Robotic Magnetic Navigation systems. Stereotaxis and Abbott have completed the integration of their technologies and performed testing demonstrating joint compatibility. The integrated technologies are cleared for use in Europe, with additional regulatory clearances expected in the coming months. Concurrently, the FDA approved Abbott's TactiFlex Ablation Catheter, Sensor Enabled. The company says it is the world's first ablation catheter with a flexible tip and contact force technology. It is

Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.

    Write first comment